Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05210413
Title Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults (SPARTO)
Acronym SPARTO
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University Hospital, Bordeaux
Indications
Therapies
Age Groups: child | senior | adult
Covered Countries FRA


No variant requirements are available.